Study on the associations between liver damage and antituberculosis drug rifampicin and relative metabolic enzyme gene polymorphisms

References

• Harding E. WHO global progress report on tuberculosis elimination. Lancet Respir Med 2020, 8: 19.
   Google Scholar
• Tr S, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1–11.
   Web of Science ®Google Scholar
• Bryant KE, Yuan Y, Engle M, et al. Group ACT and tuberculosis trials C. central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis. Contemp Clin Trials. 2021;104:106355.
   PubMed Web of Science ®Google Scholar
• O’Boyle SJ, Power JJ, Ibrahim MY. Factors affecting patient compliance with anti-tuberculosis chemotherapy using the directly observed treatment, short-course strategy (DOTS). Int J Tuberc Lung Dis. 2002;6:307–312.
   PubMed Web of Science ®Google Scholar
• Kamolratanakul P, Sawert H, Lertmaharit S, et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg. 1999;93(5):552–557.
   PubMed Web of Science ®Google Scholar
• Bastian I, Rigouts L, Van DA, et al. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull World Health Organ. 2000;78(2):238–251.
   PubMed Web of Science ®Google Scholar
• Ma J, Huang M, Wang SH, et al. Undiagnosed pleural effusion treated with traditional Chinese medicine: a case report. Explore (NY). 2021. DOI:10.1016/j.explore.2021.02.005
   Google Scholar
• Trebucq A, Decroo T, Van Deun A, et al. Regimen for multidrug-resistant tuberculosis: a decade of evidence. J Clin Med. 2019;9:55.
   PubMed Web of Science ®Google Scholar
• Salehitali S, Noorian K, Hafizi M, et al. Quality of life and its effective factors in tuberculosis patients receiving directly observed treatment short-course (DOTS). J Clin Tuberc Other Mycobact Dis. 2019;15:100093.
   PubMedGoogle Scholar
• Reckers A, Huo S, Esmail A, et al. Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1169:122467.
   PubMed Web of Science ®Google Scholar
• Verma D, Ed C, Ordway DJ. The double-edged sword of Tregs in M tuberculosis, M avium, and M. abscessus infection. Immunol Rev. 2021;301(1):48–61.
   PubMed Web of Science ®Google Scholar
• Zugazaga A, Stachno MA, Garcia A, et al. Pulmonary artery pseudoaneurysms: endovascular management after adequate imaging diagnosis. Eur Radiol. 2021;31(9):6480–6488.
   PubMed Web of Science ®Google Scholar
• Anjani QK, Permana AD, Carcamo-Martinez A, et al. Versatility of hydrogel-forming microneedles in in vitro transdermal delivery of tuberculosis drugs. Eur J Pharm Biopharm. 2021;158:294–312.
   PubMed Web of Science ®Google Scholar
• Sanjay S, Girish C, Pc T, et al. Quercetin modulates NRF2 and NF-kappaB/TLR-4 pathways to protect against isoniazid- and rifampicin-induced hepatotoxicity in vivo. Can J Physiol Pharmacol. 2021;99: 952-963.
   PubMed Web of Science ®Google Scholar
• Shehu AI, Zhu J, Li J, et al. Targeting xenobiotic nuclear receptors PXR and CAR to prevent cobicistat hepatotoxicity. Toxicol Sci. 2021;181:58–67.
   PubMed Web of Science ®Google Scholar
• Campbell IA, Bah-Sow O. Pulmonary tuberculosis: diagnosis and treatment. BMJ. 2006;332:1194–1197.
   PubMedGoogle Scholar
• Gao XF, Li J, Zw Y, et al. Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2009;13:810–819.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Ma L, Wu W, et al. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PLoS One. 2014;9:e85905.
   PubMedGoogle Scholar
• Su Q, Kuang W, Hao W, et al. (Rifampicin and Isoniazid) induce liver injury by regulating NLRP3 inflammasomes. Mediators Inflamm. 2021;2021:8086253.
   PubMed Web of Science ®Google Scholar
• Prokunina L, Alarcon-Riquelme ME. Regulatory SNPs in complex diseases: their identification and functional validation. Expert Rev Mol Med. 2004;6(10):1–15.
   PubMedGoogle Scholar
• Br W, Js L, Cp M, et al. Micropatterned coculture With 3T3-J2 fibroblasts enhances hepatic functions and drug screening utility of HepaRG cells. Toxicol Sci. 2021;181:90–104.
   PubMed Web of Science ®Google Scholar
• De R, Cargill M, Bolk S, et al. Linkage disequilibrium in the human genome. Nature. 2001;411:199–204.
   PubMed Web of Science ®Google Scholar
• Tang SW, Lv XZ, Chen R, et al. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population. Clin Exp Pharmacol Physiol. 2013;40:326–332.
   PubMed Web of Science ®Google Scholar
• Pachkoria K, Lucena MI, Ruiz-Cabello F, et al. Spanish Group for the study of drug-induced liver D. genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (Dili). Br J Pharmacol. 2007;150:808–815.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819–850.
   PubMed Web of Science ®Google Scholar
• Tolosa L, Jimenez N, Perez G, et al. Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury. Arch Toxicol. 2018;92:383–399.
   PubMed Web of Science ®Google Scholar
• Thomas L, Sekhar Miraj S, Surulivelrajan M, et al. Influence of single nucleotide polymorphisms on rifampin pharmacokinetics in tuberculosis patients. Antibiotics (Basel). 2020;9. DOI:10.3390/antibiotics9060307
   Web of Science ®Google Scholar
• Tarantino G, Di MMN, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol. 2009;15:2817–2833.
   PubMed Web of Science ®Google Scholar
• Mitchell JR. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976;84(2):181–192.
   PubMed Web of Science ®Google Scholar
• Nelson SD, Mitchell JR, Timbrell JA, et al. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science. 1976;193(4256):901–903.
   PubMed Web of Science ®Google Scholar
• Hegarty CE, Ianni AM, Kohn PD, et al. Polymorphism in the ZNF804A gene and variation in D1 and D2/D3 dopamine receptor availability in the healthy human brain: a dual positron emission tomography study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021. DOI:10.1016/j.bpsc.2020.12.006
   PubMedGoogle Scholar
• Kholina A, Kozyrenko M, Artyukova E, et al. Genetic diversity of oxytropis section xerobia (Fabaceae) in one of the centres of speciation. Genetica. 2021;149:89–101.
   PubMed Web of Science ®Google Scholar
• Medina-Montes A, Carrillo-Gonzalez DF, Hernandez-Herrea DY. Association of a genetic polymorphism in the BMPR-1B gene, and non-genetic factors with the natural prolificacy of the Colombian-haired sheep. Trop Anim Health Prod. 2021;53(2):206.
   PubMed Web of Science ®Google Scholar
• Reia TA, Da Silva RF, Jacomini AM, et al. Blood pressure in older adults with different levels of training status: the influence of polymorphisms of endothelial nitric oxide synthase. J Phys Act Health. 2021;18:516–523.
   PubMed Web of Science ®Google Scholar
• Bolt HM. Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer’s pioneering ideas to modern concepts. Drug Metab Rev. 2004;36:497–509.
   PubMed Web of Science ®Google Scholar
• Chowdhury A, Santra A, Bhattacharjee K, et al. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol. 2006;45:117–126.
   PubMed Web of Science ®Google Scholar